USA - NASDAQ:IMMX - US45258H1068 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to IMMX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-01 | HC Wainwright & Co. | Initiate | Buy |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-02-22 | Roth MKM | Initiate | Buy |
7 analysts have analysed IMMX and the average price target is 8.16 USD. This implies a price increase of 93.82% is expected in the next year compared to the current price of 4.21.
The consensus rating for IMMIX BIOPHARMA INC (IMMX) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.